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Abstract
Background: The management of hormone-refractory prostate cancer (HRPC) still remains as an important challenge
of daily oncology practice. Docetaxel has proved to be a first line treatment choice. All-trans retinoic acid (ATRA) could
potently inhibit the growth of prostate cancer cells in vitro and its combination with various anticancer agents results in
increased cytotoxicity. Based on these data, our aim was to examine the synergistic/additive cytotoxic and apoptotic
effects of combination of docetaxel and ATRA, in hormone- and drug refractory human DU-145 prostate cancer cells.
Furthermore, we have searched for the underlying mechanisms of apoptosis by demonstrating apoptosis-related genes.
Methods:  XTT cell proliferation assay was used for showing cytotoxicity. For verifying apoptosis, both DNA
Fragmentation by ELISA assay and caspase 3/7 activity measurement were used. For detecting the mechanism of
apoptosis induced by docetaxel-ATRA combination, OligoGeArray® which consists of 112 apoptosis related genes was
used.
Results: Our results revealed that docetaxel and ATRA were synergistically cytotoxic and apoptotic in DU-145 cells, in
a dose- and time dependent manner. It was also shown by our studies that apoptosis was induced in DU-145 prostate
carcinoma cells with significant cytotoxicity, no matter which agent applied first. We have found out that docetaxel-
ATRA combination significantly downregulates survivin (BIRC5), myeloid cell leukemia-1 (MCL-1) and lymphotoxin β-
receptor (LTβR) genes, which all three have pivotal roles in regulation of apoptosis and cell cycle progression.
Conclusion: In conclusion, we strongly suggest that docetaxel and ATRA combination is a good candidate for this
challenging era of daily oncologic practice. Also, the combination of docetaxel and ATRA might allow a reduction in
docetaxel doses and by this way may diminish docetaxel adverse effects while maintaining the therapeutic effect in
patients with HRPC.
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Background
Prostate cancer is the second most common cause of can-
cer death among men in developed countries [1]. In about
80% of metastatic prostate cancer patients, primary
androgen ablation leads to symptomatic improvement
and a decrease in serum prostate-specific antigen (PSA),
but in all patients the disease will eventually become
refractory to hormone treatment [2]. These patients have
a median survival of 16 to 18 months, despite modern
chemotherapy.
Docetaxel is a semisynthetic anticancer agent which
shows its activity through stabilizing microtubules during
cell division. In addition to this cytostatic ability, it can
also regulate cell signaling and expression of certain
genes. Docetaxel treatment increases Bcl-2 phosphoryla-
tion, downregulates Bcl-XL protein levels, induces p53
and antiangiogenic factors and thus results in apoptosis
[3]. Although docetaxel chemotherapy has become the
first-line standard of care for HRPC based on the results of
two large randomized trials, PSA responses rarely exceed
50% and median survival is less than 20 months, thus the
use of chemotherapy in this disease remains a subject of
active clinical investigation [4]. There are also some prob-
lems encountered during docetaxel treatment including
serious side effects in most of the patients [3,5,6]. Investi-
gators are now focused on how to enhance the cytostatic
and cytotoxic effects of docetaxel by combining it with
novel anticancer agents for the treatment of prostate can-
cer.
All-trans retinoic acid (ATRA) is a natural analog of retin-
oic acids which can regulate a number of cellular activities
including proliferation, differentiation, metabolism,
reproduction, morphogenesis, and induction of apopto-
sis. ATRA shows most of its effect by binding specific
nuclear retinoic acid receptors (RARs). Since ATRA can
regulate aberrant cell growth and induce apoptosis, it has
been widely investigated in preclinical and clinical trials
to be used in the treatment of many cancer types, includ-
ing prostate cancer [7-11]. It was also demonstrated by
different groups that ATRA can be used to increase the sen-
sitivity of different types of cancers to applied anticancer
agents [12-15].
Based on these data, we examined the synergistic/additive
effects of combination of docetaxel and the natural ana-
logue of retinoic acids, ATRA, in hormone- and drug
refractory human DU-145 prostate cancer cells. These
cells are ideal models to study the effects and mechanisms
of various anticancer agents since they represent very high
aggressive nature of metastatic human prostate cancers.
We also studied the possible apoptotic mechanisms
induced by combination of both and any agent alone in
these cells.
Materials and methods
Chemicals
Cell culture supplies were obtained from Biological
Industries (Kibbutz Beit Haemek, Israel). Docetaxel and
ATRA were obtained from Sigma Chemical Co (USA). The
stock solution of ATRA was prepared at a concentration of
83 mM in DMSO and aliquots were stored at -20°C. Stock
solution of docetaxel (10 mM) was prepared in DMSO
and the DMSO concentration in the assay did not exceed
0,1%. All the other chemicals, unless mentioned, were
obtained from Sigma (USA).
Cell lines and culture conditions
Human DU-145 prostate cancer cells were obtained from
ICLC (Genova, Italy). The cells were maintained in RPMI
1640 growth medium containing 10% heat-inactivated
fetal bovine serum (FBS), 1% L-glutamine, and 1% peni-
cillin-streptomycin at 37°C in 5% CO2.
Measurement of growth by XTT cell proliferation assay
The cytotoxic effect of ATRA, docetaxel, and combination
of both on DU145 cells were determined by using XTT cell
proliferation assay (Roche Applied Science, Mannheim,
Germany).
In short, cells (104 cells/well) were plated into 96-well
plates containing 200 μl of the growth medium in the
absence or presence of increasing concentrations of the
anticancer agents at 37°C in 5% CO2 after verifying cell
viability by trypan blue dye exclusion assay. After incuba-
tion period of 72 h, 50 μl of XTT labeling mixture was
added to each well. Finally, the optical density was meas-
ured at 490 nm with a reference wavelength at 650 nm in
a microplate reader (Beckman Coulter, DTX 880 Multi-
mode Reader). After that, the IC50 concentrations of the
compound were calculated from cell proliferation plots.
Triplicate wells were used for each treatment.
Measurement of DNA fragmentation by ELISA assay
DNA fragmentation levels were measured by ELISA using
Cell Death Detection ELISAPLUS kit (Roche Applied Sci-
ence, Mannheim, Germany). The relative amounts of
mono- and oligonucleosomes generated from the apop-
totic cells were quantified using monoclonal antibodies
directed against DNA and histones by ELISA. Briefly, cyto-
plasmic fraction of the untreated controls and ATRA or
docetaxel alone and in combination of both treated DU-
145 cells were transferred onto a streptavidin-coated plate
and were incubated at room temperature for 2 hours with
a mixture of peroxidase conjugated anti-DNA and biotin
labeled anti-histone. The plate was washed thoroughly
and incubated with 2,29-Azino-di-[3-ethylbenzthiazo-
linesulfonate] diammonium salt (ABTS) before measur-
ing the absorbance at 405 nm with a reference wavelength
of 490 nm (Beckman Coulter, DTX 880 MultimodeJournal of Experimental & Clinical Cancer Research 2008, 27:37 http://www.jeccr.com/content/27/1/37
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Reader). All the experiments were performed in duplicate
in enzyme-linked immunosorbent assay (ELISA) assays.
Measurement of caspase 3/7 enzyme activity
Caspase 3/7 enzyme activity was determined using the
Caspase-Glo 3/7 assay (Promega, Madison, WI) as
described by the manufacturer. Briefly, DU-145 cells at a
concentration of 104 cells/well were plated in a 96-well
plate in 100 μl culture medium in the absence or presence
of increasing concentrations of ATRA or docetaxel alone
and in combination of both for 72 h. Then, 100 μl of Cas-
pase-Glo 3/7 reagent was added on to each well and the
plates were incubated at room temperature for 1 more
hour. Finally, the luminescence of each sample was meas-
ured at luminometer (Beckman Coulter, DTX 880 Multi-
mode Reader).
Examining the expression levels of apoptosis specific genes 
by oligoarray
Expression levels of apoptosis specific genes were exam-
ined by human apoptosis Oligo GEArray® (SuperArray,
Frederick, MD). The Oligo GEArray® Human Apoptosis
Microarray profiles the expression of 112 genes involved
in apoptosis. This array includes TNF ligands and their
receptors, members of the Bcl-2 gene family and caspases.
Briefly, total RNA was extracted from cell samples using
an Array Grade Total RNA isolation kit (SuperArray, Fred-
erick, MD) and quantitated by UV spectroscopy using a
Eppendorf biophotometer. The integrity and quality of
the isolated RNA was determined by running the RNAs on
agarose gel electrophoresis. cDNA was labeled from total
RNA with biotin-16-dUTP and the GE Array TM Amp
Labelling-LPR Kit (SuperArray, Frederick, MD) according
to manufacturer instructions. The biotin-labeled cDNA
was then added to the membrane and hybridized over-
night to Human Apoptosis Oligo GEArray as stated by the
manufacturer. Signal detection was achieved by exposure
to CDP-Star alkaline phosphatase chemiluminescent sub-
strate (SuperArray, Frederick, MD). An image was proc-
essed using Kodak Gel Logic 1500 Imaging System and
analysed with the GEArray analyser software. Experiments
were repeated three times using RNA extracted from three
different cultures.
Statistical analysis
All experiments were set up in triplicate and the results
were expressed as the mean ± standard deviation (SD).
Statistical analysis and P values determinations were con-
ducted by the Student's t-test. The data were analyzed
using GraphPad PRISM software (version 5, CA, USA).
Median dose effect analysis was used to assess the interac-
tion between agents. Determination of the synergistic ver-
sus additive versus antagonistic cytotoxic effects of the
combination treatment of the cells by docetaxel and ATRA
was assessed by Biosoft CalcuSyn program (Ferguson,
MO, USA). CI was used to express synergism (CI < 1),
additive effect (CI = 1), or antagonism (CI > 1) [16].
Results
Effects of docetaxel and ATRA on the growth of human 
DU-145 prostate cancer cells
To evaluate the effects of docetaxel and ATRA on the
growth of human prostate cancer cells, DU-145 cells were
exposed to increasing concentrations of docetaxel (from
0,01- to 1000 nM) and ATRA (from 40- to 140 μM) for 24,
48 and 72 h. Both docetaxel and ATRA decreased cell pro-
liferation in a time- and dose dependent manner in cells
(data not shown). As shown in figure 1, there were 5-, 7-,
and 54% decreases in cell proliferation in 0,1-, 1-, and 10
nM docetaxel applied DU-145 cells, as comparing to
untreated controls at 72 h. Highest cytotoxicity was
observed at 72 h and IC50 value of docetaxel in DU-145
(figure 1) cells was calculated from cell proliferation plots
and was found to be 8,2 nM.
We conducted the same set of experiments for ATRA and
our results showed that in 40-, 80-, and 120 μM ATRA
exposed DU-145 (figure 2) cells, there were 7-, 18-, and
37% decreases in cell proliferation, as compared to
untreated controls. IC50 value of ATRA was 135 μM for
DU-145 cells (figure 2).
Exposure to combination therapy of docetaxel and ATRA 
resulted in a synergistic cytotoxicity as compared to any 
agents alone in human DU-145 prostate cancer cells
To study the possible synergistic/additive effects of
docetaxel and ATRA combination, DU-145 cells were
exposed to different concentrations of docetaxel or ATRA
alone, and in combination of both for 24, 48 and 72
hours. The synergism or additivity was calculated via com-
Cytotoxic Effects of Docetaxel on DU-145 cells Figure 1
Cytotoxic Effects of Docetaxel on DU-145 cells. The XTT 
assays were performed using triplicate samples in at least 
two independent experiments. The error bars represent the 
standard deviations, and when not seen, they are smaller 
than the thickness of the lines on the graphs. P < 0,05 was 
considered significant.
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bination index (CI) by using Biosoft Calcusyn Program.
CI = 1 indicates additive effect, CI > 1 indicates antago-
nism, CI < 1 indicates synergism and CI < 0.5 shows
strong synergy. Combination of different concentrations
of docetaxel and ATRA were evaluated at different time
points (data not shown). Results showed significant syn-
ergistic toxicity on prostate carcinoma cells at 72 h, as
compared to any agent alone as shown in table 1. The
results revealed that while 0,1 nM docetaxel and 60 μM
ATRA resulted in 5- and 13% decrease in proliferation of
DU-145 cells, respectively, the combination of both drugs
at the same doses caused 78% decrease in cell prolifera-
tion as compared to untreated controls.
The synergistic effect of combination of docetaxel and
ATRA is best observed in their lower doses as shown in fig-
ure 3. There were strong synergism calculated for 0,01 nM
docetaxel and 60 μM ATRA, 0,1 nM docetaxel and 80 μM
ATRA and 0,1 nM docetaxel and 80 μM ATRA in DU-145
cells (table 1).
Effects of the sequential treatment
The previous findings demonstrated that tumor cells with
docetaxel and ATRA resulted in significant synergy at 72 h.
We examined the effect of sequential treatment of DU-
145 cells with either docetaxel or ATRA and subsequent
treatment with the second agent. Pretreatment of tumor
cells with docetaxel for 36 h and wash and then treatment
for an additional 36 h with ATRA resulted in synergistic
cytotoxicity in DU-145 cells. Also, pretreatment of tumor
cells with ATRA for 36 h and wash and then treatment for
an additional 36 h with docetaxel resulted in synergistic
cytotoxicity in DU-145 cells (data not shown). So, we
could not show any effect of sequential treatment on syn-
ergy obtained with either of the agents.
Combination of docetaxel and ATRA induced DNA 
fragmentation significantly as compared to any agent 
alone in DU-145 prostate cancer cells
To examine the possible synergistic effects of combination
of docetaxel and ATRA, as compared to any agent alone,
on induction of DNA fragmentation as a marker of cell
death, we quantified the levels of mono-oligo nucleo-
some fragments using Cell Death Detection Plus Elisa Kit
(Roche Applied Science, Mannheim, Germany). We
treated DU-145 cells in different concentrations of
docetaxel or ATRA and the combination of both for 72
hours before analysing DNA fragmentations (figure 4).
The results showed that when DU-145 cells exposed to
0,01 nM docetaxel and 60 μM ATRA, there were 2,9- and
3,9 times increase observed in DNA fragmentation as the
combination of both induced DNA fragmentation 7,7
times more as compared to untreated controls (figure 4).
A significant increase in caspase-3/7 enzyme activity has 
been observed in response to docetaxel and ATRA 
Cytotoxic Effects of ATRA on DU-145 cells Figure 2
Cytotoxic Effects of ATRA on DU-145 cells. The XTT assays 
were performed using triplicate samples in at least two inde-
pendent experiments. The error bars represent the standard 
deviations, and when not seen, they are smaller than the 
thickness of the lines on the graphs. P < 0,05 was considered 
significant.
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Table 1: Combination index values of docetaxel or ATRA alone 
and their combination on growth inhibition of DU-145 cells. 
Concentration of drugs CI value
DOC (0,01 nM) + ATRA (60 μM) 0.254 Strong synergism
DOC (0,1 nM) + ATRA (80 μM) 0.300 Strong synergism
DOC (0,1 nM) + ATRA (60 μM) 0.219 Strong synergism
Combination index (CI) values were calculated from the XTT cell 
proliferation assays. The data represent the mean + SD of 3 
independent experiments.
Antiproliferative Effects of Combination of Docetaxel and  ATRA on DU-145 Cells Figure 3
Antiproliferative Effects of Combination of Docetaxel and 
ATRA on DU-145 Cells. Cytotoxicity was determined by the 
XTT cell proliferation test in a 72 hours culture. The results 
are expressed as the mean of three different experiments. 
The error bars represent the standard deviations, and when 
not seen, they are smaller than the thickness of the lines on 
the graphs. P < 0,05 was considered significant.
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combination as compared to any agent alone in human 
prostate cancer cells
In order to better evaluate the possible synergistic effects
of combination of docetaxel and ATRA, as compared to
any agent alone, on induction of apoptosis in human DU-
145 cells, we performed caspase 3/7 enzyme activity assay
using Caspase-Glo 3/7 Assay (Promega, Madison, WI). To
that aim, DU-145 cells were exposed various concentra-
tions of docetaxel or ATRA alone and in combination of
both for 72 h (figure 5).
In parallel with the DNA fragmentation analyses, our
results revealed that there was a dose-dependent increase
in caspase 3/7 activation both in docetaxel and ATRA
exposed DU-145 cells. Specifically, in DU-145 cells
exposed to 0,01 nM docetaxel or 60 μM ATRA, there were
1,25- and 2,5 times increases in caspase 3/7 enzyme activ-
ity, respectively, while combination of both resulted in 17
times increase in caspase 3/7 enzyme activity (figure 5) as
compared to untreated controls.
Docetaxel and ATRA combination significantly reduce 
mRNA levels of antiapoptotic survivin (BIRC5), MCL-1 and 
LTβR genes in DU-145 cells
We used apoptosis specific oligoarray to examine the
changes in expression levels of the apoptosis-related genes
in response to docetaxel (0.1 nM) and ATRA (60 μM)
treatment in DU-145 cells as compared to untreated con-
trols. These doses of both docetaxel and ATRA were cho-
sen because of best synergy obtained in cytotoxicity
experiments. mRNA expression results from this study are
presented by degree of significance of fold change. Three
repeated experiments were carried out and the results
showed that there were 3.5-, 3.3 and 4.8, fold decrease in
mRNA levels of antiapoptotic survivin (BIRC5), myeloid
cell leukemia-1 (MCL-1) and lymphotoxin β-receptor
(LTβR) genes, respectively, in DU-145 cells exposed to
combination of docetaxel and ATRA compared to
untreated controls (figure 6). These were the only genes
that have been significantly downregulated out of 112
apoptosis-related genes by the docetaxel and ATRA com-
bination treatment.
Discussion
Data presented here provide evidence that treatment of
hormone- and drug resistant prostate cancer cell line, DU-
145 with combination of docetaxel and ATRA results in a
significant synergistic cytotoxic activity and apoptosis.
The findings demonstrate that the synergistic effect of
combination of docetaxel and ATRA is best observed in
their lower doses which acceptable for in vivo administra-
tion.
We have looked for the possible underlying mechanisms
of synergy achieved by combination of docetaxel and
ATRA and we have shown that combination significantly
downregulates survivin (BIRC5), myeloid cell leukemia-1
(MCL-1) and lymphotoxin β-receptor (LTβR) genes,
which all three have pivotal roles in regulation of apopto-
sis and cell cycle progression. Since apoptosis and cell
cycle are closely linked processes, there are a number of
regulatory molecules that interface between apoptosis and
cell cycle progression. In the process of carcinogenesis,
altered regulation between apoptosis and cell cycle, in the
favor of aberrant cell proliferation, is the main mecha-
nism. Thus, these regulatory molecules take role in the
Apoptotic effects of docetaxel and ATRA alone or in combi- nation on DU-145 cells through DNA fragmentation analyses Figure 4
Apoptotic effects of docetaxel and ATRA alone or in combi-
nation on DU-145 cells through DNA fragmentation analy-
ses. The results are the means of two independent 
experiments. The error bars represent the standard devia-
tions, and when not seen, they are smaller than the thickness 
of the lines on the graphs. P < 0,05 was considered signifi-
cant.
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induction of apoptosis can also participate in the cell cycle
or vice versa. The three molecules mentioned above are
very well examples of such regulatory molecules. Also
they are all very ideal targets for cancer treatment [17,18].
Survivin (BIRC5), an antiapoptotic protein, has attracted
attention of many investigators from the point that it is
overexpressed in many types of cancer cells including gas-
tric, lung, colon, breast etc. unlike any other inhibitor of
apoptosis proteins (IAPs) [17]. Originally, it was found to
prevent cells from apoptosis and was detected highly in
the embryonic stage. Subsequently, it was shown to be up-
regulated in G2/M phase of the cell cycle and was found
to be linked with microtubules and sustained cell survival
during G2/M phase. So, survivin acts as an versatile mole-
cule of cell division and apoptosis in cancer [19,20].
Because the highly expression of survivin in many types of
cancer is associated with shortage of survival, it is one of
the possible targets for cancer treatment in the last years
[21-24].
Another such protein participating in the regulation of
both apoptosis and cell cycle is MCL-1. The MCL-1 gene
(myeloid cell leukemia-1) was discovered incidentally as
an induction gene in myeloblastic leukemia cell differen-
tiation about a decade ago and proved to be a member of
the emerging Bcl-2 gene family [25]. The antiapoptotic
Bcl-2 family member, MCL-1 is normally up- and down-
modulated in response to environmental signals and con-
ditions in a normal cell, but is constitutively expressed in
Changes in mRNA levels of apoptosis related genes in DU-145 cells exposed to docetaxel and ATRA combination as com- pared to untreated controls Figure 6
Changes in mRNA levels of apoptosis related genes in DU-145 cells exposed to docetaxel and ATRA combination as com-
pared to untreated controls. mRNA profiles of apoptosis related genes were obtained by using Oligo GEArray Human Apop-
tosis (SuperArray, Frederick, MD, USA). mRNAs were isolated from untreated, docetaxel treated, ATRA treated and 
combination of docetaxel and ATRA treated DU-145 cells. Survivin (BIRC5), MLC-1 and LTβR mRNA levels were significantly 
downregulated by combination treatment. P < 0,05 was considered significant.Journal of Experimental & Clinical Cancer Research 2008, 27:37 http://www.jeccr.com/content/27/1/37
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cancer where it promotes cell survival and drug resistance
[26]. Therefore, MCL-1 has been suggested as a potential
new therapeutic target for many types of cancer. In a
recent study done by Aicheberger at al., they examined the
expression and functional role of MCL-1 in neoplastic
mast cells and tried to determine whether MCL-1 could
serve as a target in systemic mastocytosis. They found
MCL-1 mRNA upregulation in all the patients they have
examined and moreover, they have shown that exposure
of cells to MCL-1-specific antisense oligonucleotides
(ASOs) or MCL-1-specific siRNA resulted in reduced cell
survival and increased apoptosis compared with
untreated cells [27]. So, MCL-1 is one of the important
survival factors for cancer cells and is a potent target of
cancer treatment.
The other molecule that was significantly downregulated
by docetaxel-ATRA combination in DU-145 cells is also
very good example of two-way functioning molecules,
lymphotoxin-beta receptor (LTβR). LTβR is a member of
the tumor necrosis factor family of signaling receptors that
regulate cell survival or death through activation of NF-
kappaB. These receptors transmit signals through down-
stream adaptor proteins called tumor necrosis factor
receptor-associated factors (TRAFs) [28]. Mainly, LTβR
plays an important role in development and organization
of lymphoid tissues acting as a survival factor for cells. But
because of the altered control of apoptosis and cell sur-
vival in carcinogenesis, it is up-regulated in cancer cells. In
some studies, it was clearly shown that by binding LTβR
with some specific or oligo-sense antibodies results in
decreased tumor growth and increased apoptosis in tumor
cells [28-30].
Currently, treatment of HRPC still represents a challenge
for clinicians. Since prostate cancer is a disease of elderly
men, the wide spectrum toxic side effects of cytotoxic
agents used for the treatment are another limitation of
daily oncologic practice. Standard first line docetaxel
chemotherapy has also some serious side effects in most
of the HRPC patients [3,5,6]. Thus, novel and effective
approaches may provide an important avenue for the
treatment of these groups of patients. We strongly suggest
that docetaxel and ATRA combination is a good candidate
for this challenging era of daily oncologic practice since
the combination of docetaxel and ATRA might allow a
reduction in docetaxel doses and by this way may dimin-
ish docetaxel adverse effects while maintaining the thera-
peutic effect in patients with HRPC.
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